Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors

In vivo model for mastocytosis: A comparative review

(2015) Girolamo Ranieri et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Current treatment options in patients with mastocytosis: status in 2015 and future perspectives

(2015) Michel Arock et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes

(2014) Raphael Itzykson et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG-Positive Prostate Cancer

(2014) S. Yoo et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes

(2014) K. Hanssens et al.   HAEMATOLOGICA

EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?

(2014) Rossella Terragni et al.   PLoS One

Loss of Function of TET2 Cooperates with Constitutively Active KIT in Murine and Human Models of Mastocytosis

(2014) Serena De Vita et al.   PLoS One

Sequencing and G-Quadruplex Folding of the Canine Proto-Oncogene KIT Promoter Region: Might Dog Be Used as a Model for Human Disease?

(2014) Silvia Da Ros et al.   PLoS One

Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: A retrospective cohort study

(2013) Yoshinori Takeuchi et al.   VETERINARY JOURNAL

Breed predispositions in canine mast cell tumour: A single centre experience in the United Kingdom

(2013) James Warland et al.   VETERINARY JOURNAL

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells

(2012) E. Soucie et al.   BLOOD

Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis

(2012) Fabiola Traina et al.   PLoS One

Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies

(2011) Z. Li et al.   BLOOD

Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation

(2011) Kelly Moran-Crusio et al.   CANCER CELL

Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine

(2011) S. Ito et al.   SCIENCE

Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis

(2010) T. M. Wilson et al.   HAEMATOLOGICA

Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines

(2010) Yoshinori Takeuchi et al.   VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY

IDH1 and IDH2 hotspot mutations are not found in canine glioma

(2009) Zachary J. Reitman et al.   INTERNATIONAL JOURNAL OF CANCER

Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors

(2009) K.A. Hahn et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

(2009) A Tefferi et al.   LEUKEMIA

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

(2009) A Tefferi et al.   LEUKEMIA

Acquired mutations in TET2 are common in myelodysplastic syndromes

(2009) Saskia M C Langemeijer et al.   NATURE GENETICS

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gain-of-Function Mutations in the Extracellular Domain of KIT Are Common in Canine Mast Cell Tumors

(2008) S. Letard et al.   MOLECULAR CANCER RESEARCH

Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells

(2008) Keitaro Ohmori et al.   VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY